Clinical Trials Logo
  1. Home
  2. Retinitis Pigmentosa
  3. NCT06368375
  4. Details
NCT06368375 Clinical Trial

Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa

Retinitis Pigmentosa Clinical Trial

Official title:
Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06368375
Other study ID # PRPF31-3102022BO2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2023
Est. completion date June 30, 2023

Study information
Verified date March 2024
Source University Hospital Tuebingen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective chart review study to elucidate the genotype and phenotype of patients with PRPF31-associated retinitis pigmentosa and asymptomatic carriers of the respective variant(s)

Recruitment information / eligibility
Status Completed
Enrollment 87
Est. completion date June 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - genetically confirmed PRPF31-associated inherited retinal dystrophy or asymptomatic carrier of the respective variant(s) Exclusion Criteria: - none

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Germany University Hospital Tuebingen Tuebingen Baden-Wuerttemberg

Sponsors (1)
Lead Sponsor Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Best Corrected Visual Acuity (BCVA) best corrected visual acuity September 2007 - January 2022
Primary Visual Field (VF) visual field as measured by semi-automated 90° kinetic visual field exam using target III4e September 2007 - January 2022
Primary Fundus Photography (FP) characterization of the retina with fundus photography September 2007 - January 2022
Primary Optos characterization of the retina with ultra-wide-field scanning laser ophthalmoscopy September 2007 - January 2022
Primary Autofluorescence (AF) characterization of the retina with fundus autofluorescence September 2007 - January 2022
Primary Optical Coherence Tomography (OCT) characterization of the retina with optical coherence tomography, e.g. foveal ellipsoid zone loss September 2007 - January 2022
Primary Full-Field Electroretinogram (ff-ERG) characterization of retinal function with full-field electroretinogram September 2007 - January 2022
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2